Antibody Mediated Rejection Associated With Complement Factor H–Related Protein 3/1 Deficiency Successfully Treated With Eculizumab
Open Access
- 1 September 2012
- journal article
- case report
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (9), 2546-2553
- https://doi.org/10.1111/j.1600-6143.2012.04124.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Treatment options and strategies for antibody mediated rejection after renal transplantationSeminars in Immunology, 2012
- Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumabEuropean Journal of Haematology, 2011
- Inhibiting the C5–C5a receptor axisMolecular Immunology, 2011
- Thrombotic Microangiopathy and Peritubular Capillary C4d Expression in Renal Allograft BiopsiesClinical Journal of the American Society of Nephrology, 2011
- Antibody-mediated rejection in kidney transplantation: an updateExpert Opinion on Pharmacotherapy, 2011
- Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathiesBest Practice & Research Clinical Haematology, 2009
- The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantationNephrology Dialysis Transplantation, 2009
- Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody-Mediated RejectionAmerican Journal of Transplantation, 2009
- Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft RejectionAmerican Journal of Transplantation, 2003